Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and Rose as Investor Relations Council

El Paso, Texas, July 24, 2014 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTCBB: "BIEI") a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that it has retained the investor relations firm Porter, LeVay and Rose to represent it and to implement its communications strategies.

William Hartman, President and CEO of Premier Biomedical stated, "Premier Biomedical is entering a new stage in its development, embarking on two immensely important clinical trials. We believe that transparency and openness are vital to ensuring maximum shareholder value and minimum regulatory interference. Consequently, we have retained Porter, LeVay and Rose based on their four plus decades of experience and their intimate knowledge of the special communications situations involved in bringing treatments to market. Their unique insights should prove invaluable as we undertake these trials.

Michael Porter, President of Porter, LeVay and Rose, said, "Premier Biomedical is one of the most exciting firms we have encountered in our many years of work in the biomedical field. In particular, they have two distinct technologies that, from a financial standpoint, complement each other.

"First, Premier Biomedical plans a clinical trial of its drug Feldetrex™, and it will treat patients suffering from fibromyalgia, MS, and neuropathy. Premier Biomedical received a patent for Feldetrex™ at the end of June 2014, and the Company is moving quickly to get started on the trial. The patients will be given one of four treatments: a placebo, Lyrica®, Feldetrex™ or a Lyrica-Feldetrex™ blend. The results should be available in a matter of months, and commercialization could come quickly.

"What the Company has done that makes this so interesting lies in its research partnerships. Dr. Roxanna Delgado of the US Army will conduct the clinical trial at the William Beaumont Army Medical Center (WBAMC), and she will receive the support of the medical experimentation statistical service department at the University of Texas, El Paso, under the auspices of Dr. Robert Kirken, UTEP's principal investigator."

Porter continued, "Premier Biomedical also plans to conduct a study on its core technology to physically remove the pathophysiologic basis of disease™.  It will also take place at the WBAMC immediately following the completion of the first clinical study and will be administered by the same Army-based team. The protocol will be drafted for IRB review as the first study progresses.

"The US Patent Office recently allowed 20 claims covering this basic technology underpinning Premier's on-going research into new treatments for many of today's most debilitating diseases. The idea is simple enough that non-scientists can understand it, but at the same time, it is a revolutionary approach.

"By removing these compounds from the cerebral spinal fluid of individual soldiers suffering from traumatic brain injury and/or PTSD, Premier Biomedical is removing the cause of their illnesses. The Company has already succeeded in removing these same malevolent particles from pooled CSF furnished through the WBAMC Army-based team. This may represent another step forward in the treatment of brain injuries and PTSD."

Porter concluded, "We look forward to helping Premier Biomedical tell this amazing story to the investment community.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."  http://www.premierbiomedicalinc.com/

About Porter, Levay and Rose

PLR is a premier full-service investor relations and corporate communications firm that has functioned as a principled and responsible liaison with its clients' stakeholders for four decades. PLR represents clients in a wide range of industries, including technology, biotech, medical devices, manufacturing, business services, and retail. 

Find PLR online at  www.plrinvest.com .

Safe Harbor Notice 

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contacts

Premier Biomedical, Inc.

W. Hartman, 724-633-7033

info@premierbiomedicalinc.com

 Or 

Michael Porter

Porter, LeVay and Rose

212-564-4700

mike@plrinvest.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 99

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 27

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 235

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 254

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 148

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 489

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

YouTube Shuts Down Tenet Media Channel Amid Legal Issues

Updated Category News Views 305

YouTube's Action Against Tenet Media Explained YouTube, which is part of Alphabet (NASDAQ: GOOGL), has made a significant move by shutting down the Tenet Media channel, along with four other channels managed by Lauren Chen. This decision comes in response to serious legal actions taken by the U.S. Department of Justice against certain individuals involved in money...

Continue Reading
Ardelyx Faces Class Action Lawsuit Amidst Investment Losses

Updated Category News Views 112

Important Update for Ardelyx Investors Regarding Class Action Pomerantz LLP has recently informed shareholders about a class action lawsuit involving Ardelyx, Inc. This lawsuit targets both the company and its key officers, alleging violations of federal securities laws. Investors who held Ardelyx securities during a specified timeframe should pay close attention to this...

Continue Reading
Derek Bryson Park: Innovator Transforming Finance Worldwide

Updated Category News Views 205

Celebrating Derek Bryson Park's Impact on Finance Derek Bryson Park has recently been highlighted by The Enterprise World Magazine as a key figure in the financial industry, a well-deserved recognition for his extensive and impactful career. With three decades of experience, Park continues to innovate in finance, public service, and global diplomacy. Pioneering Leadership...

Continue Reading
Understanding Currency Impacts in Global Trade Dynamics

Updated Category News Views 291

Understanding Currency Impacts in Global Trade Dynamics Scott Bessent, a noted figure in finance, is igniting conversations regarding tariffs and trade in recent discussions. All eyes on Wall Street are focused on how these changes influence market dynamics. Initially, any reduction in the U.S. trade deficit with other nations may seem like a significant win for the...

Continue Reading
Pennant Group Expands Its Operations with Recent Acquisition

Updated Category News Views 283

Pennant Group's Strategic Acquisition Announcement The Pennant Group, Inc. (NASDAQ: PNTG), a prominent holding company in the healthcare industry, recently achieved a significant milestone by acquiring specific operational assets from UnitedHealth Group Incorporated. This notable transaction was made possible due to UnitedHealth’s acquisition of Amedisys Inc., enabling...

Continue Reading